PharmaVentures establishes an office in Seoul to enhance access for South Korean biotechs
ADC Therapeutics SA Common Shares (ADCT)
Company Research
Source: PR Newswire
LONDON, March 29, 2023 /PRNewswire/ -- PharmaVentures announces its new office in Korea as part of its continued strategic expansionHeadquartered in London, UK, PharmaVentures has been assisting Korean biopharma companies for more than 5 years on various transaction and strategy projects. JungHyun Eom, Associate, is now based in Seoul, South Korea, to support current and prospective clients in the emerging Korean biotech sector.JungHyun Eom, Associate, said, "We are excited to be out in Korea communicating with these innovators closely. We will continue bringing value to the Korean bio industry and serving as the bridge between the innovation in Asia and its commercialisation to the rest of the world."Fintan Walton, Founder and CEO of PharmaVentures, said "PharmaVentures' specialist knowledge and experience of the Korean emerging biopharmaceutical sector sets us apart from other transactions advisory firms, even more so now that we have JungHyun Eom based in Korea full time. By establ
Show less
Read more
Impact Snapshot
Event Time:
ADCT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ADCT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ADCT alerts
High impacting ADC Therapeutics SA Common Shares news events
Weekly update
A roundup of the hottest topics
ADCT
News
- ADC Therapeutics Accelerates R&D with Genedata BiologicsPR Web
- ADC Therapeutics SA (NYSE: ADCT) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $9.00 price target on the stock.MarketBeat
- ADC Therapeutics SA (NYSE: ADCT) had its "buy" rating re-affirmed by analysts at Guggenheim.MarketBeat
- ADC Therapeutics Announces Updates on LOTIS-7 Clinical Trial Evaluating ZYNLONTA® in Combination with Glofitamab or Mosunetuzumab in Patients with Relapsed/Refractory B-cell Non-Hodgkin Lymphoma [Yahoo! Finance]Yahoo! Finance
- ADC Therapeutics Announces Updates on LOTIS-7 Clinical Trial Evaluating ZYNLONTA® in Combination with Glofitamab or Mosunetuzumab in Patients with Relapsed/Refractory B-cell Non-Hodgkin LymphomaGlobeNewswire
ADCT
Earnings
- 3/13/24 - Miss
ADCT
Sec Filings
- 4/16/24 - Form PRE
- 4/9/24 - Form 8-K
- 3/15/24 - Form 424B3
- ADCT's page on the SEC website